• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Braeburn Pharmaceuticals

FDA deals tentative approval to Braeburn for OUD injection

December 26, 2018 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn said this week that it won tentative FDA approval for its Brixadi extended-release weekly and monthly buprenorphine injections. The company’s product is designed for the treatment of moderate to severe opioid use disorder in people who have already started treatment with buprenorphine. The FDA acknowledged that Braeburn met all required quality, safety and efficacy […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Braeburn Pharmaceuticals

Titan, Braeburn end commercialization deal for Probuphine drug-delivery implant

May 30, 2018 By Sarah Faulkner

Braeburn Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) and Braeburn Pharmaceuticals said today that they plan to end a 2012 licensing agreement that gave Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada. Probuphine, which was developed using Titan’s ProNeura continuous drug-delivery tech, is an implant that can be placed in a patient’s upper arm in an outpatient office […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Titan Pharmaceuticals

Braeburn dealt setback over monthly, weekly opioid abuse therapy

January 22, 2018 By Sarah Faulkner

Braeburn Pharmaceuticals

The FDA has issued a complete response letter to Braeburn Pharmaceuticals, denying its application for an investigational weekly and monthly buprenorphine depot injection designed to treat adults with opioid use disorder. The company reported that the dreaded CRL does not request additional clinical studies, but Braeburn did not elaborate as to what sort of additional […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance Tagged With: Braeburn Pharmaceuticals

Braeburn raises $110m for opioid use disorder depot injection

January 11, 2018 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn Pharmaceuticals has raised $110 million in a mezzanine round of financing led by Wellington Capital. Other investors included Avista Capital Partners, RA Capital Management, Deerfield Management and Apple Tree Partners. The Princeton, N.J.-based company said it plans to use the new funds to support the FDA approval process and commercialization of CAM2038, a weekly […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance Tagged With: Braeburn Pharmaceuticals

Braeburn’s buprenorphine depot wins priority review from FDA

September 18, 2017 By Sarah Faulkner

Camurus, Braeburn Pharmaceuticals

Braeburn Pharmaceuticals said today that the FDA granted priority review to the company’s CAM2038 NDA. The investigational weekly and monthly buprenorphine depot injection was designed to treat adults with opioid use disorder. The regulatory agency is slated to make a decision about CAM2038 by January 10, 2018. “FDA’s acceptance of our NDA for CAM2038 under […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals Tagged With: Braeburn Pharmaceuticals

Braeburn, Camurus seek FDA nod for buprenorphine depot

July 20, 2017 By Sarah Faulkner

Camurus, Braeburn Pharmaceuticals

Camurus AB (STO:CAMX) and Braeburn Pharmaceuticals said today that the companies submitted a new drug application to the FDA for its weekly and monthly buprenorphine depots to treat opioid use disorder. Braeburn also reported that it applied for priority review of its application, which could potentially shorten the company’s path to the market. The NDA submission was supported […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, camurus

Titan Pharmaceuticals partners for long-acting antimalarial implant

July 17, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) this month revealed a collaboration with the Walter Reed Army Institute of Research to evaluate the use of its ProNeura drug-delivery technology for the long-term prevention of malaria. The company is already working to develop its implant for an array of applications. Titan president & CEO Sunil Bhonsle told Drug Delivery Business News that this […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Pharmaceuticals Tagged With: Braeburn Pharmaceuticals, Titan Pharmaceuticals

Camarus, Braeburn tout Phase II data for long-acting buprenorphine depot

June 23, 2017 By Sarah Faulkner

Camurus, Braeburn Pharmaceuticals

Camarus AB (STO:CAMX) and Braeburn Pharmaceuticals touted data yesterday from a Phase II trial of its long-acting buprenorphine depot. The 47-patient trial found that CAM2038 blocks the effects of opioids and suppresses withdrawal symptoms in adults with opioid use disorder. The in-patient trial included 5 3-day test sessions to evaluate the patients’ response to randomized […]

Filed Under: Clinical Trials, Featured, Pain Management, Pharmaceuticals Tagged With: Braeburn Pharmaceuticals, Camarus AB

Braeburn names former Teva exec as new president, CEO | Personnel Moves – June 14, 2017

June 14, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: alexionpharmaceuticals, AstraZeneca plc, Biogen, Boston Scientific, Braeburn Pharmaceuticals, ctibiopharma, cytrx, Dicerna Pharmaceuticals, GlaxoSmithKline plc, Merrimack Pharmaceuticals, Novartis, Ocular Therapeutix, Sanofi-Aventis, Teva Pharmaceuticals, uniqure

Braeburn, Knight seek Health Canada nod for opioid dependence implant

June 13, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn Pharmaceuticals and Knight Therapeutics (TSE:GUD) said today that Health Canada has agreed to review Knight’s new drug submission for Probuphine, a buprenorphine subdermal implant designed to treat opioid drug dependence. In February last year, Braeburn and Knight inked an exclusive distribution and sublicense deal, giving Knight the exclusive right to distribute Probuphine in Canada. Braeburn’s […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Knight Therapeutics

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS